110P - Predictive and prognostic role of T-regulatory cells in resected non-small cell lung cancer

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Non-Small Cell Lung Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Fatih Kose
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors F. Kose1, A. Findikcioglu2, T. Canpolat3, A.M. Sedef4, A. Besen5, H. Mertsoylu4, O. Ozyilkan5, H. Abali6
  • 1Medical Oncology, Baskent University Faculty of Medicine Adana Uygulama Ve Arastirma Mer., 01123 - Adana/TR
  • 2Thoracic Oncology, Baskent University Faculty of Medicine Adana Uygulama Ve Arastirma Mer., Adana/TR
  • 3Pathology, Baskent University Faculty of Medicine Adana Uygulama Ve Arastirma Mer., Adana/TR
  • 4Medical Oncology, Baskent University Faculty of Medicine Adana Uygulama Ve Arastirma Mer., 01120 - Adana/TR
  • 5Medical Oncology, Baskent University Faculty of Medicine Adana Uygulama Ve Arastirma Mer., Adana/TR
  • 6Medical Oncology, Acıbadem Adana Hastanesi, 01130 - Adana/TR

Abstract

Background

Lung cancer is the leading cause of cancer-related mortality and responsible of 1.6 million deaths per year through worldwide. Surgical resection with negative margin combined with the adjuvant therapy [except for stage IA and IB (

Methods

FOXP3 expression in tumor infiltrating lymphocytes (TIL) was examined by immunohistochemical staining from resected early stage 48 NSCLC patients. Data of patients were analyzed retrospectively. FOXP3 expression status along with common clinicohistopathological prognostic factors were evaluated retrospectively.

Results

Median age of patients was 62 years-old (range 43–78). Mean follow-up, median overall survival (OS), and disease free survival (DFS) were 49, 49, and 30 months, respectively. FOXP3 expression was positive in 23 (47.9%) patients. Adjuvant chemotherapy (4 cycle of cisplatin-vinorelbine) were given to 16 patients (33.3%) at physician discretion. Increased rate of FOXP3 expression are associated with worse OS and DFS with p value of 0.016 and 0.032, respectively. In the patients with high FOXP3 expression, platin based adjuvant chemotherapy had showed detrimental effect on DFS and OS with p value of 0.029 and 0.154 (40 vs 21 months), respectively.

Conclusions

These results suggest that FOXP3 expression in TIL has a better prognostic potential in resected NSCLC. Our findings also highlight the very high-risk group in resected NSCLC patients with high FOXP3 staining intensity who did not get any benefit even disfavor from adjuvant platin chemotherapy.

Clinical trial identification

Legal entity responsible for the study

Baskent Universiity

Funding

Turkish Society of Medical Oncology

Disclosure

All authors have declared no conflicts of interest.